Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Five Patent Applications Related to RNAi: Nov 20, 2007

Premium
Title: RNA Interference in Respiratory Epithelial Cells
 
Number: 7,297,786
 
Filed: July 11, 2005
 
Lead Inventor: Paul McCray, University of Iowa
 
The invention “is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules,” the patent’s abstract states.
 
The patent specifically claims RNAi molecules capable of inhibiting expression of respiratory syncytial virus-specific messenger RNA.
 

 
Title: Elastin-Like Polymer Delivery Vehicles
 
Number: 20070265197
 
Filed: May 11, 2007
 
Lead Inventor: Darin Furgeson, University of Wisconsin
 
According to the patent application’s abstract, the invention “concerns elastin-like polymer delivery compositions and methods for the use thereof. In some aspects, ELP compositions may be used to deliver therapeutic nucleic acids [or] polypeptides of small molecules. In some aspects, in vivo delivery with ELP compositions can directed to specific target sites by the application of local hyperthermia therapy. Compositions and methods for ELP gene therapy are provided.”
 

 
Title: Materials and Methods for Reducing Inflammation by Inhibition of the Atrial Natriuretic Peptide Receptor
 
Number: 20070265204
 
Filed: April 30, 2007
 
Lead Inventor: Shyam Mohapatra, University of South Florida
 
“This invention pertains to inhibitors of atrial natriuretic peptide receptor A function, such as small interfering RNA, useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus infection, and cancers by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy, viral infection, and/or cancer by administering such NPRA inhibitors to the subject,” the patent application’s abstract states.
 

 
Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA
 
Number: 20070265220
 
Filed: May 1, 2007
 
Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)
 
“The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene,” the patent application’s abstract states. “More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”
 

 
Title: siRNA Targeting Testes Development-Related NYD-SP21   
 
Number: 20070265437
 
Filed: June 7, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to NYD-SP21.”
 

 
Title: siRNA Targeting Polo-Like Kinase-1
 
Number: 20070265438
 
Filed: June 15, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.